1. Home
  2. Stock quotes
  3. Meridian Bioscience
  4. Financial Statements
  5. Income Statement
Meridian Bioscience logo
Meridian Bioscience VIVO

Quarterly report 2022-Q4
added 02-09-2023

report update icon

Meridian Bioscience Income Statement 2011-2026 | VIVO

Annual Income Statement Meridian Bioscience

2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

 1.35 B 865 M 771 M 415 M 680 M 591 M 631 M 696 M 647 M 832 M 638 M 564 M

Shares

 43.6 M 43.3 M 42.9 M 42.6 M 42.3 M 42.2 M 42 M 41.7 M 41.5 M 41.2 M 41.1 M 40.7 M

Historical Prices

 31.8 20.4 18.7 9.77 17.1 13.3 16.2 18 13.8 21.5 15.8 14.1

Net Income

 42.5 M 71.4 M 46.2 M 24.4 M 23.8 M 21.6 M 32.2 M 35.5 M 34.7 M 38 M 33.4 M 26.8 M

Revenue

 333 M 318 M 254 M 201 M 214 M 201 M 196 M 195 M 189 M 189 M 174 M 160 M

Cost of Revenue

 145 M 117 M 97.4 M 82.3 M 82.5 M 76.5 M 68.9 M - - - - -

Gross Profit

 188 M 201 M 156 M 118 M 130 M 125 M 128 M 122 M 117 M 121 M 110 M 99.3 M

Operating Income

 54.4 M 93 M 61.3 M 32.7 M 31.6 M 37.4 M 51.4 M 56.1 M 52.4 M 57.3 M 49.3 M 40 M

Interest Expense

 1.19 M 1.88 M 2.63 M 1.94 M 1.52 M 1.64 M 897 K -1.02 M -309 K 4 K 378 K 352 K

EBITDA

 70.9 M 108 M 74.9 M 47.3 M 52.6 M 52.1 M 60.2 M 61.3 M 58 M 62.9 M 55.9 M 45.7 M

Operating Expenses

 134 M 108 M 94.9 M 81 M 85.8 M 80.8 M 74.3 M 65.8 M 64.9 M 63.7 M 60.6 M 59.3 M

General and Administrative Expenses

 57.1 M 49.5 M 44.3 M 34.6 M 34.5 M 33 M 30.6 M 27.6 M 27.4 M 30.5 M 27.4 M 25.4 M

All numbers in USD currency

Quarterly Income Statement Meridian Bioscience

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

 43.9 M 43.8 M - 43.5 M 43.4 M 43.4 M 43.3 M 43.2 M 43.1 M 42.8 M 42.8 M 43.1 M 42.8 M 42.5 M 42.6 M 42.8 M 42.4 M 42.3 M 42.3 M 42.4 M 42.3 M 42.2 M 42.2 M 42.3 M 42.2 M 42 M 42.1 M 42.2 M 41.9 M 41.6 M 41.7 M 41.9 M 41.6 M 41.4 M 41.5 M 41.6 M 41.4 M 41.2 M 41.3 M 41.4 M 41.1 M 41.1 M 41.1 M 41.1 M 41.1 M 40.7 M 40.7 M 41.1 M

Net Income

 -29.8 M - - 28.8 M 15.3 M - 11.7 M 26.3 M 26.8 M 6.49 M 27.5 M 26.8 M 2.83 M 4.1 M 5.08 M 2.83 M 8.11 M 5.43 M 6.82 M 8.11 M 6.3 M 5.73 M 240 K 6.3 M 6.28 M 5.49 M 8.75 M 6.28 M 8.89 M 8.47 M 9.1 M 8.89 M 7.9 M 8.18 M 8.84 M 7.9 M 7.43 M 9.15 M 10.2 M 10.2 M 8.47 M 8.57 M 8.59 M 8.47 M 6.58 M 6.71 M 6.84 M 6.58 M

Revenue

 56.9 M - - 111 M 88.3 M - 63.5 M 85.3 M 92.9 M 64.2 M 84.8 M 92.9 M 47.4 M 50.8 M 48.4 M 47.4 M 51.5 M 53.1 M 51.7 M 56.5 M 52.3 M 49.7 M 50.1 M 54.1 M 46.8 M 47 M 50.7 M 46.8 M 47.2 M 47.1 M 48.2 M 47.2 M 48 M 46.7 M 47.2 M 48 M 44.8 M 49 M 47.1 M 44.8 M 45.4 M 43.5 M 41.9 M 45.4 M 40.1 M 41.3 M 40.1 M 40.3 M

Cost of Revenue

 25.4 M - - 42.8 M 39.2 M - 26.4 M 27.5 M 31.4 M 71.3 M 28.8 M 31.4 M 19.8 M 61 M 20.2 M 20 M 19.9 M 61.9 M 19.8 M 19.9 M 20.3 M 57.4 M 19 M - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

 31.5 M - - 68.5 M 49.2 M - 37.1 M 57.8 M 61.5 M 38.3 M 56 M 61.5 M 27.7 M 29.2 M 28.3 M 27.4 M 31.8 M 32.2 M 32 M 31.6 M 32 M 30.6 M 31.1 M 31.8 M 29 M 29.7 M 32.9 M 29.4 M 31.6 M 29.8 M 30.3 M 31.6 M 29.2 M 28.4 M 29.2 M 29.2 M 28 M 30.9 M 30.6 M 28 M 28.8 M 27.5 M 27.4 M 28.8 M 24.5 M 24.5 M 25.4 M 24.7 M

Operating Income

 -28.1 M - - 36.1 M 20.3 M - 15.7 M 34.2 M 34.7 M 51.8 M 34.7 M 34.7 M 5.39 M 26.8 M 6.46 M 5.39 M 10.6 M 24.5 M 8.74 M 10.6 M 8.06 M 28.6 M 4.3 M 8.06 M 10.1 M 42.5 M 13.7 M 10.1 M 13.6 M 42.8 M 14.4 M 13.6 M 12.7 M 40.4 M 13.1 M 12.7 M 11.6 M 44 M 15.7 M 11.6 M 13.1 M 37.2 M 12.6 M 13.1 M 9.8 M 30.2 M 10.1 M 9.8 M

Interest Expense

 148 K - - 341 K 372 K - 444 K 472 K 534 K 2 M 703 K 534 K 767 K 1.16 M 448 K 767 K 363 K 1.15 M 375 K 363 K 395 K 1.24 M 407 K 395 K 423 K 470 K 427 K 423 K 96 K -892 K -99 K 96 K -582 K -505 K -257 K -582 K -220 K 225 K -160 K -220 K 128 K 304 K 31 K 128 K 316 K 357 K 36 K 316 K

EBITDA

 -26.5 M - - 38.6 M 22 M - 18.8 M 36.3 M 36.2 M 55.6 M 37.1 M 36.2 M 6.61 M 30.8 M 9.03 M 6.61 M 11.8 M 27.8 M 11 M 11.8 M 9.21 M 31.8 M 6.46 M 9.21 M 11.2 M 45.4 M 15.5 M 11.2 M 14.5 M 45.4 M 16.2 M 14.5 M 13.6 M 43.1 M 14.9 M 13.6 M 12.5 M 46.6 M 17.4 M 12.5 M 13.9 M 39.9 M 14.4 M 13.9 M 10.7 M 32.7 M 11.8 M 10.7 M

Operating Expenses

 59.6 M - - 32.3 M 28.9 M - 21.4 M 23.6 M 26.9 M 66.3 M 21.3 M 26.9 M 22.3 M 62.3 M 21.8 M 22 M 21 M 74.1 M 23.2 M 21 M 23.9 M 65.1 M 26.8 M 23.7 M 19 M 55.6 M 19.2 M 19.4 M 18 M 49.3 M 15.9 M 18 M 16.6 M 48.4 M 16.1 M 16.6 M 16.4 M 46.1 M 14.9 M 16.4 M 15.7 M 44.3 M 14.8 M 15.7 M 14.7 M 44.6 M 15.2 M 14.9 M

General and Administrative Expenses

 11.1 M - - 18.6 M 14.7 M - 12 M 12.9 M 11.9 M 32.2 M 12.6 M 11.9 M 8.98 M 24.3 M 8 M 8.76 M 8.9 M 26.5 M 8.38 M 8.9 M 9.2 M 23.3 M 8.29 M 8.9 M 7.74 M 22.3 M 7.54 M 8.45 M 8.17 M 20.9 M 6.54 M 8.17 M 7.38 M 20.4 M 6.72 M 7.38 M 7.55 M 21.5 M 6.78 M 7.55 M 7.5 M 19.2 M 6.16 M 7.5 M 6.64 M 19 M 6.56 M 6.64 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Meridian Bioscience (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Centogene N.V. Centogene N.V.
CNTG
 		- -6.23 % $ 30.6 M germanyGermany
Bioventus Bioventus
BVS
 		$ 9.26 1.09 % $ 617 M usaUSA
Biodesix Biodesix
BDSX
 		$ 14.6 -3.63 % $ 1.89 B usaUSA
DarioHealth Corp. DarioHealth Corp.
DRIO
 		$ 8.45 9.74 % $ 33.7 M israelIsrael
DexCom DexCom
DXCM
 		$ 66.09 -1.12 % $ 25.8 B usaUSA
Enzo Biochem Enzo Biochem
ENZ
 		- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
 		- - $ 19.8 B usaUSA
Akumin Akumin
AKU
 		- -17.87 % $ 25.9 M canadaCanada
Check-Cap Ltd. Check-Cap Ltd.
CHEK
 		- - $ 9.42 M israelIsrael
Heska Corporation Heska Corporation
HSKA
 		- - $ 1.31 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
 		- - $ 562 M britainBritain
ICON Public Limited Company ICON Public Limited Company
ICLR
 		$ 103.08 3.09 % $ 8.5 B irlandaIrlanda
IDEXX Laboratories IDEXX Laboratories
IDXX
 		$ 573.29 -0.42 % $ 46.1 B usaUSA
Illumina Illumina
ILMN
 		$ 124.4 -1.43 % $ 19.8 B usaUSA
DermTech DermTech
DMTK
 		- -11.32 % $ 2.94 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
 		- -6.19 % $ 10.5 M usaUSA
Co-Diagnostics Co-Diagnostics
CODX
 		$ 4.4 101.83 % $ 129 M usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
 		- -61.36 % $ 2.46 M usaUSA
Medpace Holdings Medpace Holdings
MEDP
 		$ 466.6 -0.04 % $ 13.5 B usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
 		- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
 		- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
 		- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
 		- 0.12 % $ 80.1 M chinaChina
Myriad Genetics Myriad Genetics
MYGN
 		$ 4.62 -1.28 % $ 428 M usaUSA
National Research Corporation National Research Corporation
NRC
 		$ 17.52 1.98 % $ 392 M usaUSA
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
 		- -20.0 % $ 1.06 M usaUSA
Natera Natera
NTRA
 		$ 196.15 -0.62 % $ 19.3 B usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
 		- - $ 10.7 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
 		$ 165.13 -0.46 % $ 8.18 B usaUSA
Organovo Holdings Organovo Holdings
ONVO
 		- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
 		- -16.95 % $ 1.54 M usaUSA
OPKO Health OPKO Health
OPK
 		$ 1.17 -1.68 % $ 812 M usaUSA
Pacific Biosciences of California Pacific Biosciences of California
PACB
 		$ 1.35 -2.88 % $ 405 M usaUSA
Biocept Biocept
BIOC
 		- -13.05 % $ 7.29 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
 		$ 4.59 22.4 % $ 2.46 M usaUSA
PerkinElmer PerkinElmer
PKI
 		- -0.91 % $ 14.7 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
 		- - $ 21.2 M usaUSA
Personalis Personalis
PSNL
 		$ 7.32 -4.94 % $ 434 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
 		$ 1.73 2.37 % $ 7.59 M usaUSA
RadNet RadNet
RDNT
 		$ 59.41 -2.06 % $ 4.47 B usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
 		- -34.28 % $ 263 K israelIsrael
QIAGEN N.V. QIAGEN N.V.
QGEN
 		- - $ 10.6 B niderlandNiderland
Celcuity Celcuity
CELC
 		$ 114.81 4.16 % $ 4.53 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
 		- 0.22 % $ 16.8 M usaUSA
Senseonics Holdings Senseonics Holdings
SENS
 		$ 6.56 -2.96 % $ 274 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
 		$ 268.38 0.89 % $ 22.3 B usaUSA
NeoGenomics NeoGenomics
NEO
 		$ 7.76 -0.13 % $ 994 M usaUSA
Soleno Therapeutics Soleno Therapeutics
SLNO
 		$ 31.83 -0.03 % $ 1.62 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
 		- -1.84 % $ 15.3 M usaUSA
Precipio Precipio
PRPO
 		$ 27.2 -0.15 % $ 35.3 M usaUSA